Literature DB >> 10528025

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

M F Gnant1, L A Noll, K R Irvine, M Puhlmann, R E Terrill, H R Alexander, D L Bartlett.   

Abstract

BACKGROUND: Several approaches to gene therapy for cancer have yielded promising results in rodent models. The translation of these results to the clinical realm has been delayed by the lack of tumor models in large animals. We investigated the pattern of transgene (i. e., foreign or introduced gene) expression and virus vector elimination after systemic gene delivery using a thymidine kinase-negative vaccinia virus in a rabbit model of disseminated liver metastases.
METHODS: VX-2 rabbit carcinoma cells were maintained by serial transplantation in the thigh muscles of New Zealand White rabbits, and disseminated liver metastases were established by direct injection of tumor cells into the portal vein of the animals. Different doses of a recombinant thymidine kinase-negative vaccinia virus vector encoding the firefly luciferase reporter gene (i.e., transgene) were injected into tumor-bearing rabbits. Transgene activity in tumors and other organs was measured at multiple time points thereafter. The pattern of development of antibodies against the vaccinia virus vector was also examined. Two-tailed Student's paired t test was used for comparisons of transgene activity.
RESULTS: Transgene expression was increased in tumors by at least 16-fold in comparison with expression in other tissues by day 4 after vector injection (all P<. 001) and was maintained for approximately 1 week, providing evidence of tumor-specific gene delivery in this model. Rapid elimination of the circulating vector by the host immune system was observed. Anti-vector antibodies were detectable in serum as early as day 6 and were maintained for more than 3 months.
CONCLUSIONS: Tumor-specific gene delivery is possible after systemic injection of a thymidine kinase-negative vaccinia virus vector in a model of rabbit liver metastases. Although the period of transgene expression appears limited because of a rapid immune response, the therapeutic window might be sufficient for an enzyme/prodrug gene therapy approach in clinical application.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528025     DOI: 10.1093/jnci/91.20.1744

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Authors:  Tae-Ho Hwang; Anne Moon; James Burke; Antoni Ribas; Joe Stephenson; Caroline J Breitbach; Manijeh Daneshmand; Naomi De Silva; Kelley Parato; Jean-Simon Diallo; Yeon-Sook Lee; Ta-Chiang Liu; John C Bell; David H Kirn
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

2.  Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy.

Authors:  Y Hu; J Lee; J A McCart; H Xu; B Moss; H R Alexander; D L Bartlett
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer.

Authors:  Tian-Geng You; Hong-Shun Wang; Jia-He Yang; Qi-Jun Qian; Rui-Fang Fan; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

Review 4.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

5.  Combination of viral oncolysis and tumor-specific immunity to control established tumors.

Authors:  Chi-Mu Chuang; Archana Monie; Annie Wu; Sara I Pai; Chien-Fu Hung
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

Review 6.  Systemic tumor-specific gene delivery.

Authors:  Max Kullberg; Ryan McCarthy; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2013-09-11       Impact factor: 9.776

7.  Oncolytic viruses in the treatment of bladder cancer.

Authors:  Kyle G Potts; Mary M Hitt; Ronald B Moore
Journal:  Adv Urol       Date:  2012-07-29

8.  Angiotensin II increases gene expression after selective intra-arterial adenovirus delivery in a rabbit model assessed using in vivo SSTR2-based reporter imaging.

Authors:  Sheela P Singh; Murali K Ravoori; Katherine A Dixon; Lin Han; Sanjay Gupta; Rajesh Uthamanthil; Kenneth C Wright; Vikas Kundra
Journal:  EJNMMI Res       Date:  2016-03-17       Impact factor: 3.138

Review 9.  Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.

Authors:  Dmitriy Zamarin; Sari Pesonen
Journal:  Hum Gene Ther       Date:  2015-08       Impact factor: 5.695

Review 10.  Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.

Authors:  Padma Sampath; Steve H Thorne
Journal:  Oncolytic Virother       Date:  2013-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.